| CTRI Number |
CTRI/2026/03/106486 [Registered on: 18/03/2026] Trial Registered Prospectively |
| Last Modified On: |
26/05/2026 |
| Post Graduate Thesis |
No |
| Type of Trial |
Observational |
|
Type of Study
|
Cross Sectional Study |
| Study Design |
Other |
|
Public Title of Study
|
Clinical validation of DR AI software |
|
Scientific Title of Study
|
Clinical Validation of an Autonomous Online AI-based diagnostic system for the Detection of Diabetic Retinopathy |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Lavanya KC |
| Designation |
Medical Director |
| Affiliation |
Ravi Superspeciality Eye Hospital, A Unit of Oculus Eye Organisation, Bangalore |
| Address |
Amrutahalli, Ravi Superspeciality Eye Hospital, A Unit of Oculus Eye Organisation, Bangalore
Bangalore KARNATAKA 560092 India |
| Phone |
9449136311 |
| Fax |
|
| Email |
lavanyakc4686@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Aparna Gunda |
| Designation |
Clinical Research Head |
| Affiliation |
Oivi Tech |
| Address |
B block, 3rd floor, Sree rama Deevena, 21, Ulsoor Rd, Yellappa Garden, Bangalore KARNATAKA 560008 India |
| Phone |
9966619702 |
| Fax |
|
| Email |
aparna@oivi.co |
|
Details of Contact Person Public Query
|
| Name |
Khaleel Udyawar |
| Designation |
CTO and Co-Founder |
| Affiliation |
Oivi Tech |
| Address |
B block, 3rd floor, Sree rama Deevena,
Bangalore KARNATAKA 560008 India |
| Phone |
919886925921 |
| Fax |
|
| Email |
khaleel@oivi.co |
|
|
Source of Monetary or Material Support
|
| Oivi Tech Pvt Ltd,
Sree Rama Deevena - 3rd Floor B Block,
No 21 Ulsoor Road,
Bengaluru-560 008,
Karnataka
India
|
|
|
Primary Sponsor
|
| Name |
Oivi Tech Pvt Ltd |
| Address |
Oivi Tech Pvt Ltd,
Sree Rama Deevena - 3rd Floor B Block,
No 21 Ulsoor Road,
Bengaluru 560 008,
Karnataka
India |
| Type of Sponsor |
Other [software] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Lavanya KC |
Ravi Superspeciality Eye Hospital, A unit of Oculus Eye Organisation, Bangalore |
Amruthahalli Bangalore KARNATAKA |
09449136311
lavanyakc4686@gmail.com |
|
Details of Ethics Committee
Modification(s)
|
| No of Ethics Committees= 2 |
| Name of Committee |
Approval Status |
| Sri Sidhhartha Medical COllege |
Approved |
| Sri Venkateshware Hospital Ethics Committee |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: E089||Diabetes mellitus due to underlying condition without complications, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
NIL |
NIL |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
90.00 Year(s) |
| Gender |
Both |
| Details |
1) Before enrollment, a documented diagnosis of diabetes mellitus, e.g.:
a) Documented diagnosis of Haemoglobin A1c (HbA1c) more than or equal to 6.5 percentage within 3 months of study initiation
OR
b) Fasting Plasma Glucose (FPG) more than or equal to 126 mg per dL (7.0 mmol per L) within 10 days of study initiation
2) Age 18 or older
3) Understand the study and volunteer to sign the informed consent
|
|
| ExclusionCriteria |
| Details |
1) Diagnosed with radiation retinopathy or retinal vein occlusion.
2) Floaters
3) Participant is hypersensitive to light
4) Participant recently underwent photodynamic therapy
5) Participant is taking medication that causes photosensitivity
|
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
| Measure of sensitivity and specificity for mtmDR against reference standards |
Baseline |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| NIL |
NIL |
|
|
Target Sample Size
|
Total Sample Size="281" Sample Size from India="281"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
30/03/2026 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
Recruitment Status of Trial (Global)
Modification(s)
|
Open to Recruitment |
| Recruitment Status of Trial (India) |
Open to Recruitment |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
| Diabetes is a burning problem that is on rise worldwide. By 2050 it is estimated that 1.31 billion people will be living with Diabetes Mellitus (DM), most of them with type 2 DM. In 2021, 95.4% of older adult diabetics had disability-adjusted life years (DALYs). DR is one of the major complications of DM and is the leading cause of vision impairment both in developed and developing countries. In a recent cross-sectional study conducted in 2021 that investigated the prevalence of DR in DM patients aged above 40 years, it was estimated that an alarming 21 million have vision impairment and 2.4 million are blind due to DR. Interestingly, undiagnosed DM had an odd’s ratio of 2 for vision-threatening DR. A systematic DR screening would reduce this burden to a larger extent. Although high-income countries have successfully implemented DR screening programs, in countries like India it is partial. Many nations use 2–4 fields fundus images, this has proven effective with 80–98% sensitivity and 86–100% specificity compared to the traditional seven-field evaluation or dilated clinical examination for DR. While numerous DR algorithms exist, a majority have been validated using high-end, expensive fundus cameras. This reliance on costly equipment poses significant challenges, particularly in resource-limited settings and primary care centres, where access to such technology is often constrained. This limitation reduces patient participation in screening programs, hindering early detection efforts. To address these barriers, the Oivi DR-AI system has been developed to work seamlessly with the Oivi fundus camera—a cost-effective alternative that can capture images quickly and efficiently. Every algorithm developed must be validated within the intended population to demonstrate its efficacy and identify associated risks. Validation studies are crucial to establishing the clinical utility of the device in real-world settings. The findings from this study build trust, instil confidence among clinicians, and ultimately encourage the adoption of such innovations, ensuring their effective integration into everyday practice. | |